Acetaminophen
Small molecule targets FAAH, TRPV1 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | OFIRMEV | — | 2017-01-27 | fda.gov ↗ |
| Approved | US (FDA) | NEOPAP | — | 1968-11-07 | fda.gov ↗ |
Trials 565 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 015 trials | ||||||
| Phase 0 | NCT06462573 | Sep 2024 → Sep 2026 expected | ureterolithiasis | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06561672 | Sep 2024 → Mar 2025 overdue | — | Zagazig University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06514222 | Jul → Aug 2024 overdue | impacted teeth, multiple | University of Sharjah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06294743 | Nov 2023 → Dec 2025 | dysmenorrhea | Taichung Armed Forces General Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05122351 | Oct 2021 → Dec 2022 | — | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT04612920 | Dec 2020 → Mar 2023 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 0 | NCT04648540 | Dec 2020 → Aug 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT04059172 | Dec 2019 → Jun 2028 expected | persistent idiopathic facial pain | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 0 | NCT03763084 | Feb 2019 → Feb 2020 | delirium, paracetamol poisoning | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 0 | NCT03820193 | Jan 2019 → Jun 2020 | substance-related disorder | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT03878693 | Jul → Oct 2018 | — | University of Arizona | Completed | No outcome recorded |
| Phase 0 | NCT03383133 | Jan 2018 → Feb 2023 | — | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT02540512 | Jul → Sep 2017 | musculoskeletal system disorder | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 0 | NCT03221998 | Jul 2017 → Mar 2019 | morbid obesity | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 0 | NCT02366065 | Jan 2015 → May 2016 | glaucoma | Johns Hopkins University | Completed | No outcome recorded |
| Phase 169 trials | ||||||
| Phase 1 | NCT07710729 | Jul 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07632274 | Jun → Sep 2026 expected | — | HALEON | Recruiting | No outcome recorded |
| Phase 1 | NCT07502001 | Apr → Dec 2026 expected | obesity disorder | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07525791 | Apr 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07269756 | Dec 2025 → Mar 2026 | obesity disorder | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07429032 | Apr → Nov 2025 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT06920056 | Mar → Jul 2025 | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06701305 | Jun 2024 → Feb 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06214468 | Jan 2024 → Apr 2025 | poisoning | University of South Alabama | Completed | No outcome recorded |
| Phase 1 | NCT06186622 | Jan → Jul 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06137469 | Dec 2023 → Mar 2024 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06036784 | Sep 2023 → Nov 2024 | postgastrectomy syndrome | MBX Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05844995 | Sep 2023 → Feb 2024 | — | Johnson & Johnson Consumer Inc. (J&JCI) | Completed | No outcome recorded |
| Phase 1 | NCT07095816 | May 2023 → Feb 2025 | neoplasm | Nanjing Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05995704 | Mar → Jul 2023 | — | VectivBio AG | Completed | No outcome recorded |
| Phase 1 | NCT05564819 | Sep 2022 → May 2023 | childhood acute lymphoblastic leukemia | Nanjing Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05406752 | Jul 2022 | — | Unither Pharmaceuticals, France | Completed | No outcome recorded |
| Phase 1 | NCT04741139 | Sep 2021 → Dec 2022 | autoimmune thrombocytopenia | Baylor College of Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT04941040 | Jul → Oct 2021 | supratentorial cancer | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04571996 | Oct 2020 → Feb 2021 | central nervous system disorder | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT06782204 | Jul 2020 → Jan 2021 | hypertensive disorder | Hospital da Luz, Portugal | Completed | No outcome recorded |
| Phase 1 | NCT04265456 | Jan → Jun 2020 | — | Nevakar, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04230252 | Jan → Feb 2020 | — | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 1 | NCT04214691 | Dec 2019 → Jan 2020 | — | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 1 | NCT04424420 | Nov 2019 → Mar 2021 | — | Prof. Jürgen Brockmöller | Unknown | No outcome recorded |
| Phase 1 | NCT03953287 | Aug → Dec 2019 | — | Kolding Sygehus | Unknown | No outcome recorded |
| Phase 1 | NCT05428306 | Oct → Nov 2018 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03648437 | Sep 2018 → Oct 2024 | patent ductus arteriosus | University of Oulu | Terminated | No outcome recorded |
| Phase 1 | NCT03415243 | Mar 2018 | common cold | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03137030 | Sep 2017 → Jan 2018 | substance-related disorder | Grünenthal GmbH | Withdrawn | No outcome recorded |
| Phase 1 | NCT03103022 | Jun 2017 → Apr 2019 | patent ductus arteriosus | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT03182595 | Mar 2017 → Jan 2018 | — | Hospital da Luz, Portugal | Completed | No outcome recorded |
| Phase 1 | NCT02966860 | Aug → Sep 2016 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT02618395 | Dec 2015 → Jan 2016 | — | Sun Pharma Advanced Research Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02641899 | Dec 2015 → Mar 2016 | — | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02174068 | Jul 2014 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT02305017 | Mar → Apr 2014 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02206178 | Sep 2013 → Jan 2014 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT02095704 | May 2013 | — | Central South University | Completed | No outcome recorded |
| Phase 1 | NCT03223506 | Mar 2013 → Dec 2017 | brain injury | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02561741 | Dec 2012 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT01734759 | Nov 2012 → Jan 2013 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01606059 | May → Jun 2012 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01880125 | Jan → May 2012 | — | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01562704 | Jan → Apr 2012 | pain agnosia | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT01520792 | Nov 2011 → May 2013 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT01211912 | Sep 2010 → Dec 2011 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01188525 | Aug 2010 → Jul 2011 | — | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 1 | NCT01767428 | Apr 2010 | headache disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01053650 | Jan → Feb 2010 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT01592227 | Dec 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01540734 | Dec 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01476189 | Nov → Dec 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01476215 | Nov 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00982215 | Sep → Oct 2009 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT01476176 | Jul → Aug 2009 | headache disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01551836 | Jun 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00750048 | Sep → Nov 2008 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00750347 | Sep → Oct 2008 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00772967 | Jun → Nov 2008 | osteoarthritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00973232 | May → Aug 2008 | — | Labopharm Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00493246 | Jun 2007 → Nov 2008 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT02514941 | Jun 2007 → Mar 2010 | morbid obesity | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT01116596 | Feb 2007 → Feb 2008 | chronic pain syndrome | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00429468 | Jan 2007 → ? | — | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00428909 | Nov 2006 → Aug 2008 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00411190 | Oct → Dec 2006 | osteoarthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01517555 | Oct 2006 → May 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00653315 | May → Aug 2002 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1/211 trials | ||||||
| Phase 1/2 | NCT06256211 | Mar → Nov 2024 | patent ductus arteriosus | Soha mahmoud Hussien mahdy | Unknown | No outcome recorded |
| Phase 1/2 | NCT05742763 | Nov 2023 → Oct 2024 | osteoarthritis, knee | QC Kinetix LLC | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04015557 | Feb → Jun 2022 | classic homocystinuria | Hospital de Clinicas de Porto Alegre | Suspended | No outcome recorded |
| Phase 1/2 | NCT03997851 | Jul 2019 → Mar 2020 | — | University of Miami | Completed | No outcome recorded |
| Phase 1/2 | NCT03641209 | Sep 2018 → Nov 2023 | — | Outi Aikio | Completed | No outcome recorded |
| Phase 1/2 | NCT03617900 | Aug 2018 → May 2019 | puerperal disorder | Thammasat University | Completed | No outcome recorded |
| Phase 1/2 | NCT03528343 | Sep → Dec 2017 | appendicitis | University of Utah | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03184649 | May → Sep 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02654860 | Nov 2016 → Feb 2019 | — | Sintetica SA | Completed | No outcome recorded |
| Phase 1/2 | NCT01026961 | Sep → Nov 2010 | — | Novartis | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01086722 | Feb 2010 → Feb 2013 | morbid obesity | Hospital del Mar Medical Research Institute (IMIM) | Completed | No outcome recorded |
| Phase 260 trials | ||||||
| Phase 2 | NCT06689943 | Apr 2025 → Dec 2028 expected | strabismus | Ann & Robert H Lurie Children's Hospital of Chicago | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05685225 | Jan → Dec 2025 | migraine disorder | Allodynic Therapeutics, Inc | Withdrawn | No outcome recorded |
| Phase 2 | NCT06658574 | Nov 2024 → May 2026 | — | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT06345716 | Apr 2024 → Mar 2025 overdue | urinary tract obstruction | University of Monastir | Recruiting | No outcome recorded |
| Phase 2 | NCT05477875 | Feb 2024 → Jan 2025 | hyperopia, myopia | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT06009926 | Dec 2023 → Feb 2026 overdue | cancer, hematopoietic and lymphoid system neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06152796 | Dec 2023 → Sep 2025 | patent ductus arteriosus | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT07528118 | Aug 2023 → Jun 2024 | — | Sargodha Medical College | Completed | No outcome recorded |
| Phase 2 | NCT05340582 | Dec 2022 → Jan 2027 expected | patent ductus arteriosus | Mount Sinai Hospital, Canada | Recruiting | No outcome recorded |
| Phase 2 | NCT06371144 | Jun → Sep 2022 | — | Darlington-Peter Chibuzor Ugoji | Completed | No outcome recorded |
| Phase 2 | NCT04676802 | Dec 2021 → Feb 2027 expected | neuropathy, painful, osteoarthritis, hand | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT03792295 | Jul → Dec 2021 | — | Khashayar Vaziri | Withdrawn | No outcome recorded |
| Phase 2 | NCT04447040 | Nov 2020 → Apr 2021 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | No outcome recorded |
| Phase 2 | NCT04221165 | Aug 2020 → Sep 2023 | head and neck cancer, mucositis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2 | NCT04495283 | Jul → Nov 2020 | — | Nevakar, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05764707 | Jan 2020 → Jan 2023 | vertebral column disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03879408 | May → Nov 2019 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | No outcome recorded |
| Phase 2 | NCT03767933 | Apr 2019 → Mar 2023 | musculoskeletal system disorder | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT03679013 | Apr → Jul 2019 | — | Inova Health Care Services | Completed | No outcome recorded |
| Phase 2 | NCT03818919 | Jan 2019 → Dec 2020 | rotator cuff syndrome | Henry Ford Health System | Completed | No outcome recorded |
| Phase 2 | NCT03399318 | Jan 2019 → Dec 2022 | epilepsy, malaria, parasitemia | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT03701074 | Dec 2018 → Oct 2020 | bronchopulmonary dysplasia, patent ductus arteriosus | University of South Alabama | Terminated | No outcome recorded |
| Phase 2 | NCT03559985 | Aug 2018 → Oct 2020 | neuropathy, painful | University Hospital, Clermont-Ferrand | Terminated | No outcome recorded |
| Phase 2 | NCT03521102 | Aug 2018 → Oct 2021 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03428230 | Aug 2018 → Oct 2019 | neuropathy, painful | Sintetica SA | Completed | No outcome recorded |
| Phase 2 | NCT03570554 | Jun 2018 → Jun 2019 | osteoarthritis, knee | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT03652818 | Jun → Sep 2018 | dental pulp disorder | Nevakar, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03635684 | May 2018 → Jun 2020 | — | Saint-Joseph University | Completed | No outcome recorded |
| Phase 2 | NCT03194555 | Aug 2017 → Jul 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT03201393 | Aug 2017 → Jul 2018 | chronic pain syndrome, radiculopathy | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT06245902 | Feb 2017 → Feb 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT03061734 | Feb 2017 → Feb 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT02625454 | Dec 2016 → May 2019 | — | Richmond University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02422966 | Dec 2015 → Jan 2019 | patent ductus arteriosus | Angelini Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02532322 | Nov 2015 → Jun 2018 | Chiari malformation, childhood infratentorial neoplasm | Children's National Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT02578251 | Oct 2015 → Mar 2016 | — | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02320708 | Dec 2014 → Apr 2015 | — | Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02133326 | Mar 2014 → Jan 2017 | impacted teeth, multiple | Tufts University School of Dental Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT02815189 | Feb 2014 → Feb 2016 | — | Universidad Autonoma de Baja California | Completed | No outcome recorded |
| Phase 2 | NCT01958320 | Dec 2013 → Jun 2017 | intestinal perforation, necrotizing enterocolitis, patent ductus arteriosus | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT01960114 | Oct 2013 → Apr 2014 | dental pulp disorder | McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02108990 | Sep 2013 → Jun 2014 | borderline personality disorder | Ohio State University | Completed | No outcome recorded |
| Phase 2 | NCT01938261 | Aug 2013 → Jul 2024 | patent ductus arteriosus | University of Oulu | Completed | No outcome recorded |
| Phase 2 | NCT01739361 | Apr → Dec 2013 | infectious disease with sepsis | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT01691690 | Oct 2012 → Nov 2015 | tonsillitis | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02417337 | Aug 2012 → Aug 2014 | pulpitis | University of Khartoum | Completed | No outcome recorded |
| Phase 2 | NCT01906762 | Jul 2012 → Feb 2013 | urinary system disorder | Seyed Mehdi Pourafzali | Completed | No outcome recorded |
| Phase 2 | NCT01559259 | Apr → Sep 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01291654 | Apr 2012 → Dec 2014 | patent ductus arteriosus | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01231139 | Oct 2010 → Dec 2013 | traumatic brain injury | Dr. M.K. Saxena | Completed | No outcome recorded |
| Phase 2 | NCT01630343 | Jan 2010 → Apr 2012 | — | Queen Elizabeth Hospital, Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT00758836 | Dec 2008 → Aug 2009 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00841841 | Mar 2006 → Mar 2008 | — | University Center of Araraquara | Completed | No outcome recorded |
| Phase 2 | NCT00281684 | Dec 2005 → Oct 2007 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00528658 | Jan 2005 → Dec 2008 | — | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT00404183 | Aug 2004 → Mar 2005 | — | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00371696 | Dec 2001 → Dec 2003 | osteoarthritis | University of Bristol | Completed | No outcome recorded |
| Phase 2 | NCT00029770 | Sep 2001 → May 2007 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2 | NCT00003346 | Nov 1997 → Feb 2003 | cutaneous melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00012857 | ? → Mar 2001 | Alzheimer disease | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2/313 trials | ||||||
| Phase 2/3 | NCT06653465 | Jun 2025 → Jun 2027 expected | delirium | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04939987 | Aug → Oct 2022 | — | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04986839 | Sep 2021 → Dec 2023 | patent ductus arteriosus | Manchester University NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2/3 | NCT04414995 | Jun → Nov 2020 | — | Indonesia University | Completed | No outcome recorded |
| Phase 2/3 | NCT04360135 | May 2020 → Mar 2021 | — | Montefiore Medical Center | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04038307 | Aug 2019 → Feb 2020 | — | Cairo University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03786029 | Apr → Jun 2019 | — | Latakia University | Completed | No outcome recorded |
| Phase 2/3 | NCT03825809 | Jan 2019 → Jan 2020 overdue | substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03818932 | Jan 2019 → Jan 2020 | — | Henry Ford Health System | Completed | No outcome recorded |
| Phase 2/3 | NCT03185143 | Jun 2017 → May 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2/3 | NCT02056223 | Jan 2017 → Oct 2019 | patent ductus arteriosus, respiratory distress syndrome in premature infants | University of Padova | Suspended | No outcome recorded |
| Phase 2/3 | NCT01328808 | Oct 2011 → Oct 2021 | — | John van den Anker | Unknown | No outcome recorded |
| Phase 2/3 | NCT00525967 | Feb 2006 → Oct 2007 | cancer | Faculdade de Medicina do ABC | Unknown | No outcome recorded |
| Phase 399 trials | ||||||
| Phase 3 | NCT07225634 | Sep 2026 → Mar 2027 expected | — | AFT Pharmaceuticals, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06994442 | Dec 2025 → Jul 2029 expected | acute respiratory failure | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 3 | NCT07017452 | Aug → Dec 2025 overdue | benign prostatic hyperplasia | University of Manitoba | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06721819 | Jun 2025 → Jun 2029 expected | delirium | Beth Israel Deaconess Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT05118672 | Mar → Aug 2025 | influenza | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT07323914 | Mar 2025 → Jan 2027 expected | Alzheimer disease | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 3 | NCT05070650 | Sep 2024 → Apr 2025 | common cold | Sandoz | Withdrawn | No outcome recorded |
| Phase 3 | NCT06863636 | Sep 2024 → Oct 2025 overdue | osteoarthritis, hip, osteoarthritis, knee | Laboratorios Silanes S.A. de C.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT05845008 | Jan → Jul 2024 | — | Johnson & Johnson Consumer Inc. (J&JCI) | Withdrawn | No outcome recorded |
| Phase 3 | NCT05868122 | Sep 2023 → May 2024 | — | Johnson & Johnson Consumer Inc. (J&JCI) | Completed | No outcome recorded |
| Phase 3 | NCT05246644 | Jun 2023 → Sep 2024 | delirium | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Phase 3 | NCT05761574 | May 2023 → May 2024 | — | Johnson & Johnson Consumer Inc. (J&JCI) | Completed | No outcome recorded |
| Phase 3 | NCT04251351 | Dec 2021 → Jun 2024 | Plasmodium falciparum malaria, acute kidney injury | University of British Columbia | Unknown | No outcome recorded |
| Phase 3 | NCT05051735 | Oct 2021 → Feb 2026 | cancer | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04959591 | Jun 2021 → Apr 2022 | scoliosis | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04640376 | Mar 2021 → Nov 2022 | — | Unither Pharmaceuticals, France | Completed | No outcome recorded |
| Phase 3 | NCT02985671 | Jan → Sep 2021 | — | Ache Laboratorios Farmaceuticos S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT04429022 | Nov 2020 → May 2022 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT04093219 | Aug 2020 → Mar 2026 | coronary artery disorder, delirium | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04176419 | Jan 2020 → Jun 2021 | — | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT03508167 | Jan → Oct 2020 | — | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04038346 | Oct 2019 → May 2025 | Lyme disease, arthritic joint disease | Desiree Neville, MD | Terminated | No outcome recorded |
| Phase 3 | NCT04005755 | Jul 2019 → Jun 2020 | — | AFT Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03907176 | Apr 2019 → Oct 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03553498 | Nov 2018 → May 2019 | — | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03554018 | Oct 2018 → Sep 2019 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03584373 | Jul 2018 → Mar 2022 | nephrolithiasis | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03586934 | Jun 2018 → Jun 2019 | substance-related disorder | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT03485625 | Mar 2018 → Apr 2019 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT03404518 | Feb → Oct 2018 | — | Loma Linda University | Completed | No outcome recorded |
| Phase 3 | NCT03343392 | Nov → Dec 2017 | — | Universidade Estadual de Ponta Grossa | Completed | No outcome recorded |
| Phase 3 | NCT03330119 | Oct 2017 → Jun 2018 | pregnancy disorder, substance-related disorder | Brest, Norman A., M.D. | Terminated | No outcome recorded |
| Phase 3 | NCT03657810 | Aug 2017 → Apr 2018 | — | Charleston Laboratories, Inc | Completed | No outcome recorded |
| Phase 3 | NCT03224403 | Jul 2017 → Apr 2018 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | No outcome recorded |
| Phase 3 | NCT04037514 | Jul 2017 → Dec 2024 | patent ductus arteriosus | Máximo Vento Torres | Completed | No outcome recorded |
| Phase 3 | NCT02737124 | Feb 2017 → Mar 2018 | — | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 3 | NCT02730364 | Feb → Apr 2017 | respiratory tract infectious disorder | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT02678234 | Feb → Apr 2017 | respiratory tract infectious disorder | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT03056391 | Oct 2016 → Feb 2018 | malaria | Menzies School of Health Research | Completed | No outcome recorded |
| Phase 3 | NCT04762147 | Oct 2016 → Jun 2017 | — | Aga Khan University | Completed | No outcome recorded |
| Phase 3 | NCT03024814 | Oct 2016 → Oct 2018 | intracerebral hemorrhage | King Saud Medical City | Unknown | No outcome recorded |
| Phase 3 | NCT03192566 | Aug 2016 → Aug 2024 | obesity disorder | Children's National Research Institute | Suspended | No outcome recorded |
| Phase 3 | NCT03131713 | Jul 2016 → Dec 2017 | skin cancer | Tufts Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03537144 | Jun 2016 → Sep 2018 | patent ductus arteriosus | University of Tennessee | Terminated | No outcome recorded |
| Phase 3 | NCT02735122 | Apr → Oct 2016 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | No outcome recorded |
| Phase 3 | NCT02477007 | Dec 2015 → Nov 2018 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02487108 | Aug 2015 → Mar 2016 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02311881 | Jan 2015 → Feb 2016 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02156154 | Dec 2014 → Mar 2019 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 3 | NCT02462850 | Oct 2014 → Jan 2015 | — | Charleston Laboratories, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01973205 | Oct 2013 → Jul 2014 | migraine disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01448057 | Jul 2013 → Aug 2015 | Achoo syndrome, nasal cavity disorder, respiratory tract infectious disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01842633 | Apr 2013 → Mar 2015 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT01606319 | Feb 2013 → Apr 2015 | asthma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01755728 | Jan 2013 → Dec 2018 | patent ductus arteriosus | Hillel Yaffe Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01780428 | Jan → Oct 2013 | — | Charleston Laboratories, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01722864 | Nov 2012 → Feb 2013 | chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT01635101 | Jun 2012 → Aug 2015 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT01586143 | May 2012 → May 2013 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 3 | NCT01586962 | May 2012 | respiratory tract infectious disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01421433 | May → Aug 2012 | — | Farmoquimica S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT01402375 | Jan 2012 → Nov 2014 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01451385 | Sep 2011 → Jun 2012 | osteoarthritis | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT01432977 | Sep 2011 → Jun 2012 | pain agnosia | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 3 | NCT01394718 | Jul 2011 → Jun 2014 | — | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 3 | NCT01115673 | Jun 2010 → Jan 2011 | — | McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01112267 | May → Oct 2009 | — | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 3 | NCT01229449 | Jan → Sep 2009 | — | Reckitt Benckiser Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00736853 | Jun 2008 → Jan 2009 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00736957 | May 2008 → Oct 2009 | chronic pain syndrome | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00662818 | Mar 2008 → Sep 2009 | heart disorder, migraine disorder, peripheral vascular disease, transient ischemic attack | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00737048 | Mar → Sep 2008 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00573170 | Feb 2008 → Aug 2009 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00598702 | Jan → Dec 2008 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00598559 | Jan → Nov 2008 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00564486 | Nov 2007 → Sep 2008 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00564629 | Aug → Oct 2007 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00496015 | Jul 2007 → Mar 2008 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00493311 | Jun → Oct 2007 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00406679 | Nov 2006 → Oct 2007 | neuropathy, painful | Baxter Healthcare Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00399568 | Nov 2006 → Sep 2007 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT00434681 | Oct 2006 → Apr 2007 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00370318 | Sep 2006 → Apr 2007 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00325949 | May 2006 → May 2007 | chronic pain syndrome | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00300924 | Mar 2006 → Jan 2007 | migraine disorder | Diamond Headache Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00147355 | Nov 2005 → Nov 2008 | HIV infectious disease | Kirby Institute | Terminated | No outcome recorded |
| Phase 3 | NCT00210847 | Dec 2003 → May 2005 | diabetic polyneuropathy | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00236535 | Dec 2003 → Oct 2004 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT01771978 | Jun 2002 → Feb 2008 | ischemic disease | University Hospital, Strasbourg, France | Unknown | No outcome recorded |
| Phase 3 | NCT00092313 | Jun → Sep 2002 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00092326 | Jun → Sep 2002 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00240786 | Apr 2002 → Mar 2003 | osteoarthritis | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 3 | NCT00390260 | Feb 2002 → Feb 2003 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00110474 | May 2000 → Dec 2002 | osteoarthritis, knee | Rottapharm | Completed | No outcome recorded |
| Phase 3 | NCT00568295 | Oct 1999 → Oct 2000 | osteoarthritis, knee | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 3 | NCT02183688 | Sep 1998 → Jan 2003 | migraine disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00000425 | Jul 1996 → Apr 2001 | osteoarthritis | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT00240799 | ? → Oct 2004 | osteoarthritis | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 3 | NCT00240773 | ? → Jun 2003 | osteoarthritis, hip, osteoarthritis, knee | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 4200 trials | ||||||
| Phase 4 | NCT07536425 | Apr 2026 → Oct 2027 expected | — | Western Galilee Hospital-Nahariya | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07512297 | Apr → Dec 2026 expected | nephrolithiasis, ureterolithiasis | University of Gaziantep | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07368738 | Apr 2026 → Apr 2027 expected | — | Horizon Health Network | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07571252 | Apr → Dec 2026 expected | — | University of Puerto Rico | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07440069 | Feb → Aug 2026 overdue | — | Universidad Nacional Autonoma de Honduras | Recruiting | No outcome recorded |
| Phase 4 | NCT07235995 | Dec 2025 → Jan 2027 expected | delirium | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07169227 | Sep → Oct 2025 overdue | — | Baskent University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06950840 | Aug 2025 → May 2027 expected | chorioamnionitis | Wolfson Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07076069 | Jul 2025 → Jun 2028 expected | rotator cuff syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06757075 | Apr 2025 → Mar 2027 expected | — | Boston University | Recruiting | No outcome recorded |
| Show all 200 trials opens the full record — a long page | ||||||
| Phase not applicable98 trials | ||||||
| — | NCT07435493 | Nov 2026 expected | adenoid hypertrophy, obstructive sleep apnea syndrome | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07539961 | Sep 2026 → Dec 2027 expected | calcific tendinitis | University Hospital Dubrava | Not yet recruiting | No outcome recorded |
| — | NCT07426744 | Mar → Aug 2026 overdue | — | Muhammad Aamir Latif | Not yet recruiting | No outcome recorded |
| — | NCT07463482 | Mar → Sep 2026 expected | — | Thammasat University | Not yet recruiting | No outcome recorded |
| — | NCT07618494 | Feb → May 2026 | dental pulp disorder | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT07264309 | Nov 2025 → Dec 2026 expected | — | Zohar Nachum | Recruiting | No outcome recorded |
| — | NCT07310524 | Sep → Nov 2025 | — | Muhammad Rahman Efendi Nasution | Completed | No outcome recorded |
| — | NCT07154433 | Sep 2025 → May 2026 | osteochondritis dissecans | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT06767969 | May 2025 → Jan 2027 expected | ischemic stroke | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06917118 | May → Nov 2025 overdue | — | University of Puerto Rico | Not yet recruiting | No outcome recorded |
| — | NCT06430697 | Feb 2025 → Aug 2027 expected | — | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| — | NCT07368790 | Oct 2024 → May 2025 | — | Queen Savang Vadhana Memorial Hospital, Thailand | Completed | No outcome recorded |
| — | NCT07125911 | Apr 2024 → Apr 2025 | periapical periodontitis | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06304181 | Mar → Aug 2024 | — | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Unknown | No outcome recorded |
| — | NCT06174363 | Dec 2023 → Dec 2025 overdue | breast cancer | Yonsei University | Recruiting | No outcome recorded |
| — | NCT06015711 | Aug 2023 → Aug 2026 overdue | substance-related disorder | Ajou University School of Medicine | Recruiting | No outcome recorded |
| — | NCT05757388 | Mar → May 2023 | — | Khon Kaen University | Unknown | No outcome recorded |
| — | NCT05685342 | Feb 2023 → Feb 2025 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT06638086 | Jan 2023 → Jan 2024 | — | Rawalpindi Medical College | Completed | No outcome recorded |
| — | NCT06188143 | Dec 2022 → Jun 2023 | — | Phramongkutklao College of Medicine and Hospital | Completed | No outcome recorded |
| — | NCT07394491 | Nov 2022 → Feb 2023 | — | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
| — | NCT05366777 | Oct 2022 → Jul 2023 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT05509244 | Sep 2022 → Aug 2023 | female reproductive system disorder | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT05396677 | Mar 2022 → Jun 2023 | — | University of Guelph | Completed | No outcome recorded |
| — | NCT05248152 | Jan 2022 → Jan 2024 | — | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT04933058 | Dec 2021 → Oct 2022 | female infertility due to oocyte meiotic arrest | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT06574516 | Nov 2021 → Aug 2022 | — | King Abdullah University Hospital | Completed | No outcome recorded |
| — | NCT05069311 | Oct 2021 → Mar 2022 | chronic pain syndrome, inflammatory disease | Udayana University | Completed | No outcome recorded |
| — | NCT04882202 | Oct 2021 → Dec 2024 | aortic disorder | Gangnam Severance Hospital | Unknown | No outcome recorded |
| — | NCT04935515 | Apr → May 2021 | COVID-19 | Manimarane Arjunan, MD,DM (Cardiology) | Completed | No outcome recorded |
| — | NCT04793490 | Mar → Nov 2021 | intracranial hypotension | Ain Shams University | Completed | No outcome recorded |
| — | NCT04566250 | Feb 2021 → Apr 2022 | — | McMaster University | Completed | No outcome recorded |
| — | NCT04690673 | Jan → Mar 2021 | — | Johanna Kujala | Completed | No outcome recorded |
| — | NCT04202406 | Jan → May 2021 | pulpitis | Cairo University | Completed | No outcome recorded |
| — | NCT04593160 | Jan → Dec 2021 | pulpitis | Cairo University | Unknown | No outcome recorded |
| — | NCT04653506 | Nov 2020 → Jul 2022 | — | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT04087317 | Jun 2020 → Jun 2022 | postpartum depression, substance-related disorder | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT05393414 | Nov 2019 → Mar 2020 | — | University of Puerto Rico | Completed | No outcome recorded |
| — | NCT04042948 | Jun → Nov 2019 | lumbar disk disease, lumbar spinal stenosis, radiculopathy | Peking University Third Hospital | Completed | No outcome recorded |
| — | NCT03859102 | Dec 2018 → Oct 2019 | aneurysm or dilatation of ascending aorta, aortic valve disorder, cardiac valvular defect, coronary artery disorder +2 | James Cook University Hospital | Unknown | No outcome recorded |
| — | NCT04202224 | Oct 2018 → Feb 2019 | — | Lithuanian University of Health Sciences | Completed | No outcome recorded |
| — | NCT03644147 | Aug 2018 → Jan 2021 | female reproductive system disorder | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT03413371 | Apr 2018 → Dec 2022 | — | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT04176783 | Mar 2018 → Jul 2021 | — | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| — | NCT03389243 | Jan 2018 → Sep 2021 | — | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT04003350 | Dec 2017 → Nov 2018 | osteoarthritis, knee | Rothman Institute Orthopaedics | Completed | No outcome recorded |
| — | NCT03400111 | Sep 2017 → Mar 2019 | malposition of teeth with or without hypodontia/oligodontia | Damascus University | Completed | No outcome recorded |
| — | NCT03518463 | Jun → Jul 2017 | pregnancy disorder | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT03105830 | May 2017 → Apr 2018 | — | Western Galilee Hospital-Nahariya | Unknown | No outcome recorded |
| — | NCT03008876 | Jan 2017 → Jun 2019 | patent ductus arteriosus | Albany Medical College | Completed | No outcome recorded |
| — | NCT03011567 | Jan 2017 → Oct 2019 | hypertension, pregnancy-induced | MemorialCare Health System | Completed | No outcome recorded |
| — | NCT03297073 | Nov 2016 → Apr 2018 | liver disorder, paracetamol poisoning | University Hospital, Lille | Completed | No outcome recorded |
| — | NCT03122561 | Nov 2016 → Jan 2018 | — | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| — | NCT03035045 | Nov 2016 → Jun 2017 | — | Department of Medical Services Ministry of Public Health of Thailand | Unknown | No outcome recorded |
| — | NCT02833584 | Sep 2016 → Dec 2017 | dengue disease, liver disorder | Phramongkutklao College of Medicine and Hospital | Completed | No outcome recorded |
| — | NCT02700451 | Mar 2016 → Dec 2021 | lumbar disk disease, osteoarthritis, spine, spinal stenosis, spondylosis | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| — | NCT02973581 | Feb 2016 → Feb 2017 | — | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT03391284 | Feb 2016 → Feb 2018 | — | Scripps Health | Completed | No outcome recorded |
| — | NCT02440399 | Jul 2015 → May 2017 | — | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT02205983 | Jan 2015 → Jul 2016 | — | University of Chicago | Completed | No outcome recorded |
| — | NCT02252419 | Oct 2014 → Feb 2015 | pharyngitis | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT02219698 | Jul 2014 → Jul 2015 | diverticulitis | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT02402543 | Jun 2014 → May 2017 | anal fistula, anogenital human papillomavirus infection, hemorrhoid | University of Vermont | Completed | No outcome recorded |
| — | NCT02881996 | Jun 2014 → Jun 2016 | appendicitis | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| — | NCT01982799 | Feb 2014 → Sep 2015 | tooth disorder | University of Minnesota | Withdrawn | No outcome recorded |
| — | NCT02267772 | Jan 2014 → Apr 2019 | — | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| — | NCT03261310 | May 2013 → Jul 2018 | — | Brooke Army Medical Center | Unknown | No outcome recorded |
| — | NCT02750696 | Apr 2013 → Dec 2014 | suppurative periapical periodontitis | Federal University of Rio Grande do Sul | Completed | No outcome recorded |
| — | NCT01822821 | Mar 2013 → Dec 2014 | — | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT01823224 | Feb 2013 → Jun 2015 | gallbladder disorder | Defense and Veterans Center for Integrative Pain Management | Completed | No outcome recorded |
| — | NCT02622802 | Nov 2012 → Dec 2016 | pregnancy disorder | University Hospital, Gasthuisberg | Completed | No outcome recorded |
| — | NCT01764048 | Nov 2012 → Jan 2014 | — | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT01641289 | Jul 2012 → Sep 2014 | malaria | University of Oxford | Completed | No outcome recorded |
| — | NCT01608308 | Jul 2012 → Sep 2014 | chronic rhinosinusitis | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| — | NCT01552993 | Mar → Oct 2012 | pulmonary immaturity, retinopathy of prematurity | St. Olavs Hospital | Terminated | No outcome recorded |
| — | NCT01527942 | Mar 2012 → Jul 2013 | obesity disorder | Trinity Health Of New England | Terminated | No outcome recorded |
| — | NCT01073748 | Mar 2010 → Mar 2011 | asthma | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT00970450 | Nov 2009 → Mar 2010 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT01137591 | Apr 2009 → ? | acute liver failure, drug-induced liver injury | Columbia University | Withdrawn | No outcome recorded |
| — | NCT00386243 | Dec 2007 → May 2012 | chronic pain syndrome | VA Office of Research and Development | Completed | No outcome recorded |
| — | NCT00561288 | Nov 2007 → May 2008 | — | University of Toronto | Completed | No outcome recorded |
| — | NCT01073709 | Nov 2007 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT01079078 | Oct → Nov 2007 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT01366313 | Sep 2007 → Mar 2011 | — | Procare Riaya Hospital | Completed | No outcome recorded |
| — | NCT00536068 | Aug 2006 → Aug 2007 | vascular hemostatic disease | Kantonsspital Graubünden | Completed | No outcome recorded |
| — | NCT01523080 | May 2006 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT01513668 | May 2006 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT00389272 | Sep 2005 → Dec 2008 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| — | NCT00245375 | Jan → Dec 2005 | gallbladder disorder | Nova Scotia Health Authority | Completed | No outcome recorded |
| — | NCT00253773 | Jan 2005 → Nov 2007 | disorder of defective peroxisome oxidative status | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| — | NCT01321710 | Dec 2004 → May 2008 | pregnancy disorder, puerperal disorder, sleep disorder | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT00646906 | Jun 2004 → Jan 2012 | arthritic joint disease, myocardial infarction | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT01762891 | Mar 2003 → Jul 2006 | antiphospholipid syndrome | Hospital Universitario Pedro Ernesto | Completed | No outcome recorded |
| — | NCT00137059 | Nov 2002 → May 2005 | poisoning | Dr. Marco L.A. Sivilotti | Completed | No outcome recorded |
| — | NCT00474721 | Nov 2002 → Feb 2004 | — | University of California, San Diego | Completed | No outcome recorded |
| — | NCT00188071 | Sep 2002 → Aug 2003 | — | University Hospital, Angers | Completed | No outcome recorded |
| — | NCT00429624 | Sep 1994 → Jan 2007 | — | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT00000731 | ? → May 1990 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 845 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 017 trials | ||||||
| Phase 0 | NCT07711522 Background | Aug 2026 → Jul 2027 expected | — | Istanbul Medipol University Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07211399 Background | Jul 2026 → Dec 2030 | substance-related disorder | Jacques E. Chelly | Withdrawn | No outcome recorded |
| Phase 0 | NCT07400471 Comparator | Feb 2026 → Mar 2027 expected | — | Chattogram International Dental College | Recruiting | No outcome recorded |
| Phase 0 | NCT06642025 Background | Sep 2024 → Aug 2026 overdue | acute myeloid leukemia | Zhimin Zhai | Recruiting | No outcome recorded |
| Phase 0 | NCT07016451 Background | Apr 2024 → Sep 2025 | radiation cystitis | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 0 | NCT06212830 Comparator | Feb 2024 → Feb 2025 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 0 | NCT05013437 Background | Sep → Dec 2023 | plasma cell myeloma | Koen van Besien | Withdrawn | No outcome recorded |
| Phase 0 | NCT07204379 Comparator | Jan → Jul 2023 | — | Armed Forces Institute of Dentistry, Pakistan | Completed | No outcome recorded |
| Phase 0 | NCT04682743 Comparator | Jan 2021 → Jan 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT04123717 Comparator | Oct 2019 → Mar 2024 | — | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 0 | NCT06484439 Background | Feb 2018 → Nov 2021 | impacted teeth, multiple, neuropathy, painful | United States Naval Medical Center, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT03062488 Comparator | Oct 2017 → Jul 2018 | — | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 0 | NCT03475693 Background | Sep 2017 → Nov 2019 | traumatic encephalopathy | Corewell Health South | Completed | No outcome recorded |
| Phase 0 | NCT03088306 Comparator | Jul 2017 → May 2018 | lumbar disk degenerative disorder, lumbar spinal stenosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT02393339 Comparator | Feb 2017 → Jan 2020 | neuropathy, painful, pain agnosia | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 0 | NCT02837614 Background | Oct 2015 → Jan 2016 | impacted teeth, multiple | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 0 | NCT02373254 Comparator | Jan → Oct 2015 | — | University of California, Davis | Completed | No outcome recorded |
| Phase 159 trials | ||||||
| Phase 1 | NCT07508241 Background | Mar 2026 → Jan 2027 expected | obesity disorder | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07013643 Background | Jun 2025 → Jul 2027 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06955741 Background | May → Sep 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06812936 Comparator | Feb → Sep 2025 overdue | — | University of Baghdad | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06762600 Background | Jan 2025 → Mar 2026 | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06723691 Background | Dec 2024 → Jun 2025 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06498713 Comparator | Nov 2024 → Dec 2026 expected | — | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06513104 Background | Jul 2024 → Sep 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06460961 Background | Jul 2024 → Jul 2027 expected | metastatic malignant neoplasm | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06461039 Background | Jun 2024 → Mar 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05647681 Comparator | Jul 2023 → Jul 2024 | — | University of Monastir | Unknown | No outcome recorded |
| Phase 1 | NCT05511025 Background | Sep 2022 → Dec 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05211336 Background | Apr 2022 → Jun 2024 overdue | diffuse large B-cell lymphoma of the central nervous system | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05035407 Background | Mar 2022 → Jul 2025 | — | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT04599634 Background | Dec 2021 → Mar 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT05129137 Comparator | Nov → Dec 2021 | — | Unither Pharmaceuticals, France | Completed | No outcome recorded |
| Phase 1 | NCT04840615 Background | Jun → Dec 2021 | mesothelioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT04903509 Background | Jun 2021 → Aug 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04681105 Background | Nov 2020 → Aug 2025 | B-cell acute lymphoblastic leukemia, CD4+/CD56+ hematodermic neoplasm, Hodgkins lymphoma, T-cell acute lymphoblastic leukemia +4 | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT04580121 Background | Nov 2020 → Aug 2023 | acute myeloid leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04407234 Background | Sep 2020 → Jan 2021 | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03805932 Background | Oct 2019 → Jul 2023 overdue | hairy cell leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04074174 Background | Sep 2019 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03893175 Background | May 2019 → Mar 2022 | impacted teeth, multiple | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT05428293 Comparator | Feb → Mar 2019 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03640247 Comparator | Nov 2018 → Dec 2019 | parathyroid gland disorder, thyroid gland disorder | MetroHealth Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03649165 Background | Sep → Oct 2018 | plexiform neurofibroma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03385057 Comparator | Sep 2018 → Jan 2023 | — | Massachusetts Eye and Ear Infirmary | Withdrawn | No outcome recorded |
| Phase 1 | NCT03258593 Background | Jun 2018 → Aug 2022 | urinary bladder neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03448393 Background | Mar 2018 → Jul 2024 | B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT04330547 Comparator | Feb 2018 → Feb 2019 | akinetic mutism, brain injury | University of Liege | Completed | No outcome recorded |
| Phase 1 | NCT03567941 Background | Dec 2017 → Oct 2018 | — | Sun Pharma Advanced Research Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02240407 Background | Oct 2017 → Aug 2021 | glycogen storage disease II | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT03137017 Comparator | Sep → Nov 2017 | substance-related disorder | Grünenthal GmbH | Withdrawn | No outcome recorded |
| Phase 1 | NCT02973958 Background | Feb 2017 → Jun 2018 | balanitis, neuropathy, painful, paraphimosis | Alberta Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02648490 Background | Sep 2016 → Jun 2019 | cancer | Henlix, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02867800 Background | Jul 2016 → Dec 2021 | graft versus host disease, sickle cell disease | Monica Bhatia | Completed | No outcome recorded |
| Phase 1 | NCT02797522 Background | Jun → Nov 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03012763 Comparator | Apr 2016 → Jan 2017 | — | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT02583594 Background | Dec 2015 → Mar 2016 | multiple sclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT02188719 Background | Dec 2014 → Jun 2019 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1 | NCT02269735 Background | Nov 2014 → Jul 2016 | type 1 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02694653 Comparator | Oct 2014 → Dec 2017 | — | University of Tennessee Graduate School of Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT01998971 Background | Feb 2014 → Jan 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02452450 Comparator | Jan → Oct 2014 | — | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
| Phase 1 | NCT01951716 Background | Jan 2013 → Jul 2018 | — | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT01607905 Background | Jun 2012 → Mar 2016 | cancer | Karyopharm Therapeutics Inc | Completed | No outcome recorded |
| Phase 1 | NCT01776515 Comparator | Jan → Mar 2012 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01485198 Comparator | Aug 2011 → Aug 2013 | osteoarthritis, knee | Hospital Universitario Dr. Jose E. Gonzalez | Completed | No outcome recorded |
| Phase 1 | NCT01390441 Background | Jul 2011 → Apr 2014 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01635608 Comparator | Apr → Jul 2011 | — | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT01790009 Comparator | Feb → Jun 2011 | — | University of Reading | Completed | No outcome recorded |
| Phase 1 | NCT01551797 Comparator | May → Oct 2010 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01381640 Comparator | Apr → May 2010 | — | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT01540721 Comparator | Dec 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00840853 Background | Apr 2009 → Apr 2016 overdue | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia | Baylor College of Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01568749 Comparator | Dec 2008 → Aug 2009 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00802087 Comparator | Nov → Dec 2008 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03554005 Background | Dec 1997 → Mar 2001 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/223 trials | ||||||
| Phase 1/2 | NCT07227597 Background | Jan 2026 → Nov 2030 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06647407 Background | Nov 2024 → May 2027 expected | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06467318 Comparator | Sep 2023 → Sep 2024 | pneumothorax | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT06004687 Comparator | Jul 2023 → May 2024 | cognitive disorder | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05319730 Background | May 2023 → Jun 2027 expected | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04990388 Background | Oct 2021 → Mar 2023 | glycogen storage disease III | Ultragenyx Pharmaceutical Inc | Terminated | No outcome recorded |
| Phase 1/2 | NCT04791761 Background | Apr 2021 → Jul 2023 | adenoid hypertrophy, substance-related disorder | David Chi, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT04591600 Background | Jul → Sep 2020 | COVID-19 | Alkarkh Health Directorate-Baghdad | Completed | No outcome recorded |
| Phase 1/2 | NCT04294459 Background | Jun 2020 → May 2022 | immune system disorder | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT04324606 Background | Apr 2020 → Feb 2025 | Coronaviridae infectious disease | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT04224558 Background | Nov 2019 → Sep 2027 expected | Crohn disease | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05547659 Comparator | Jan 2019 → Apr 2020 | — | October 6 University | Completed | No outcome recorded |
| Phase 1/2 | NCT03496545 Background | Nov 2018 → Nov 2019 | intracerebral hemorrhage, ischemic stroke, subarachnoid hemorrhage, traumatic brain injury | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/2 | NCT03618823 Background | Oct 2018 → May 2020 | adenoid hypertrophy | David Chi, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT03554473 Background | Sep 2018 → Jun 2022 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03493945 Background | May 2018 → Oct 2024 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02933255 Background | Apr 2017 → Jun 2023 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02858310 Background | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02711826 Background | Sep 2016 → Aug 2023 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT02474199 Background | Jun 2016 → Dec 2019 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT02356159 Background | Sep 2015 → Dec 2024 | Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00923910 Background | Feb 2008 → Oct 2013 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00078559 Background | Nov 2003 → Feb 2010 | kidney disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2107 trials | ||||||
| Phase 2 | NCT07094542 Comparator | Sep 2026 → Nov 2029 expected | impacted teeth, multiple, myofascial pain syndrome | Rutgers, The State University of New Jersey | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07709000 Background | Aug 2026 → Nov 2033 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07102459 Comparator | Jul 2025 → Jan 2026 | — | Latigo Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT06356571 Background | Mar 2025 → Jan 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT06505187 Background | Feb 2025 → Sep 2026 expected | — | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Show all 107 trials opens the full record — a long page | ||||||
| Phase 2/325 trials | ||||||
| Phase 2/3 | NCT07570173 Background | May 2026 → Oct 2033 expected | B-cell acute lymphoblastic leukemia | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07699601 Comparator | May → Oct 2026 expected | — | Shanghai Huilun Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07098962 Comparator | Aug → Dec 2025 | — | Kastamonu University | Completed | No outcome recorded |
| Phase 2/3 | NCT07067177 Comparator | Jan → Oct 2025 | patent ductus arteriosus | Al-Quds University | Completed | No outcome recorded |
| Phase 2/3 | NCT06222320 Comparator | Jan → Oct 2024 | — | Kastamonu University | Completed | No outcome recorded |
| Phase 2/3 | NCT05597878 Comparator | Apr 2023 → Feb 2026 | prostate cancer, substance-related disorder | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT05783206 Background | Feb 2022 → Jul 2023 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | No outcome recorded |
| Phase 2/3 | NCT05293132 Background | Feb 2022 → Jun 2023 | infectious disease with sepsis | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT04920838 Comparator | Apr 2021 → Aug 2023 | COVID-19 | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 2/3 | NCT04562610 Comparator | Nov 2020 → Oct 2024 | vertebral column disorder | University of California, Davis | Completed | No outcome recorded |
| Phase 2/3 | NCT04459117 Comparator | Oct 2020 → Jun 2024 | patent ductus arteriosus | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 2/3 | NCT04254679 Comparator | Jan → Sep 2020 | — | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 2/3 | NCT03367988 Background | Dec 2018 → Jan 2023 | drug dependence | University of South Florida | Unknown | No outcome recorded |
| Phase 2/3 | NCT03604796 Comparator | Sep 2018 → Sep 2021 | patent ductus arteriosus | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 2/3 | NCT03496389 Background | Jul 2018 → Jul 2019 | — | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
| Phase 2/3 | NCT03055507 Background | Apr → Dec 2017 | chronic rhinosinusitis | University of Washington | Completed | No outcome recorded |
| Phase 2/3 | NCT02811991 Comparator | Jun 2016 → Sep 2018 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT03626753 Comparator | Jan → Jun 2015 | puerperal infection | Centre de Maternité de Monastir | Completed | No outcome recorded |
| Phase 2/3 | NCT02002741 Comparator | Aug 2014 → May 2017 | patent ductus arteriosus | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 2/3 | NCT01958866 Comparator | Oct 2013 → Dec 2014 | — | Chulalongkorn University | Completed | No outcome recorded |
| Phase 2/3 | NCT01988298 Comparator | Oct 2013 → Feb 2015 | hypertensive disorder | Complejo Hospitalario Dr. Arnulfo Arias Madrid | Completed | No outcome recorded |
| Phase 2/3 | NCT01021696 Comparator | Nov 2009 → Jul 2010 | dementia | University of Bergen | Completed | No outcome recorded |
| Phase 2/3 | NCT00969176 Comparator | Sep 2009 → Dec 2010 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2/3 | NCT01755702 Comparator | Jul 2009 → Mar 2010 | headache disorder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2/3 | NCT00137969 Background | May 2005 → Aug 2008 | systemic lupus erythematosus | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3144 trials | ||||||
| Phase 3 | NCT07296770 Background | Oct 2026 → Dec 2027 expected | chronic pain syndrome | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07225140 Comparator | Oct 2026 → Oct 2027 expected | — | AFT Pharmaceuticals, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06980727 Comparator | Aug 2026 → Dec 2027 expected | urinary tract obstruction | University of Monastir | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07525219 Comparator | Jul 2026 → Jul 2027 expected | — | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07419295 Background | Apr 2026 → Jul 2029 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Show all 144 trials opens the full record — a long page | ||||||
| Phase 4259 trials | ||||||
| Phase 4 | NCT07605065 Comparator | Nov 2026 → Feb 2027 expected | headache disorder | Pak Emirates Military Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07634393 Comparator | Aug 2026 → Jun 2028 expected | traumatic brain injury, traumatic encephalopathy | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07595302 Comparator | Jul 2026 → Jun 2027 expected | pelvis syndrome | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07600697 Background | Jul 2026 → Jul 2027 expected | female stress incontinence, pelvic organ prolapse | University of California, Los Angeles | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07625267 Background | Jul 2026 → Jun 2028 expected | diverticulitis of colon | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Show all 259 trials opens the full record — a long page | ||||||
| Phase not applicable211 trials | ||||||
| — | NCT06861387 Background | Sep 2026 → Jul 2028 expected | — | St. Antonius Hospital | Recruiting | No outcome recorded |
| — | NCT07658521 Background | Jul → Dec 2026 expected | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| — | NCT07642674 Comparator | Jun 2026 → Jan 2027 expected | — | Eskisehir Osmangazi University | Recruiting | No outcome recorded |
| — | NCT07620665 Comparator | Jun 2026 → May 2028 expected | — | Gangnam Severance Hospital | Recruiting | No outcome recorded |
| — | NCT07640126 Background | Jun 2026 → Jun 2028 expected | radiculopathy, spondylosis, cervical | University of Medicine and Pharmacy at Ho Chi Minh City | Recruiting | No outcome recorded |
| Show all 211 trials opens the full record — a long page | ||||||
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-02-06 | Daiichi Sankyo | Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use daiichisankyo.com ↗ |
| 2005-07-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Tramadol And Acetaminophen Tablets tevapharm.com ↗ |
Evidence & citations 167 cited values
Every value below carries the sentence it was read from. 1,446 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acetaminophen | “Recommended rescue medications include tocilizumab for treatment of cytokine release syndrome (CRS); dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related...” NCT07227597 ↗873“The primary objective of this study is to evaluate the analgesic efficacy of hydrocodone bitartrate/acetaminophen immediate-release tablets at doses of 5.0 milligrams (mg)/325...” NCT02487108 ↗ “Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19,...” PMID 25465228 ↗ Dec 2014 “Biphasic immediate-release (IR)/extended-release (ER) hydrocodone bitartrate (HB)/acetaminophen (APAP) 7.5/325-mg tablets are formulated with gastroretentive ER drug delivery...” PMID 26614499 ↗ Nov 2015 “The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior...” NCT00245375 ↗ “Recommended rescue medications are pegfilgrastim or equivalent, histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent,...” NCT07419295 ↗ “patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy, Cascavel, PR, Brasil) and ketorolac tromethamine oral 10 mg (Toragesic® 10...” NCT03343392 ↗ “A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites...” NCT05563961 ↗ “This clinical trial is being conducted to compare concentrations of hydrocodone and acetaminophen in the blood after administration of different amounts of tablets of a new and...” NCT03137030 ↗ “After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications,...” NCT03471442 ↗ “The ice packs, Tylenol, and Toradol regimen consists of around-the-clock ice packs, around-the-clock oral acetaminophen, around-the-clock intravenous ketorolac, and intravenous...” PMID 31201808 ↗ Jun 2019 “acetaminophen (APAP), N-acetylcysteine (NAC) and APAP in combination with NAC will inhibit lipid peroxidation in aneurysmal subarachnoid hemorrhage (aSAH), utilizing F2-IsoPs...” NCT00585559 ↗ “Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after...” NCT03554005 ↗ “The goal of this study was to compare the effectiveness of intravenous non-steroidal anti-inflammatory medication (dexketoprofen) with paracetamol (acetaminophen) in the...” PMID 24394884 ↗ Jan 2014 “Additional recommended rescue medications are histamine-1 (H1) receptor antagonist, H2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent, at the...” NCT06356311 ↗ “Efficacy and Safety Study of the Fixed-dose Combination of Celecoxib/Acetaminophen Compared to Celecoxib for the Treatment of Pain in Patients Diagnosed With Osteoarthritis in...” NCT06863636 ↗ “Participants who belong to the experimental arm will be given a single 'per os' dose of percocet (325mg acetaminophen + 7.5mg oxycodone) and lorazepam 1 mg, 30 minutes prior to...” NCT07017452 ↗ “The current standard of practice at Cooper for orthopedic surgeons performing this procedure is oxycodone 5mg PRN, ibuprofen 600mg every 6 hours, and acetaminophen 1000mg every 8 hours.” NCT05974423 ↗ “Patients will receive conservative treatment Acetaminophen (paracetamol) 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.” NCT07095569 ↗ “MNK-155, a biphasic (immediate-release/extended-release) hydrocodone bitartrate/N-acetyl-p-aminophenol (acetaminophen) (IR/ER HB/APAP) 7.5/325-mg fixed-dose combination analgesic agent” PMID 25913923 ↗ Apr 2015 “Fentanyl-Based Analgesia will receive intraoperative fentanyl (1 μg/kg IV) with standard anesthetic care with postoperative rescue analgesia with acetaminophen (15 mg/kg) as needed.” NCT07435493 ↗ “A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years” NCT07632274 ↗ “500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.” NCT04580121 ↗ “Participants were randomized to receive 5 mg of hydrocodone with 300 mg of acetaminophen (opioid) or 400 mg of ibuprofen and 500 mg of acetaminophen (nonopioid).” PMID 39755971 ↗ Jan 2025 “Intraoperatively: Intravenous Dexamethasone 0.1mg/kg (maximum dose of 8mg), Magnesium 2g, Acetaminophen 1000mg, and local infiltration of 0.5% Ropivacaine 20ml” NCT07076069 ↗ “The proposed model involves interaction of chemical exposure (2 doses of acetaminophen, APAP, 15 mg/kg) and 2 days of sulfur amino acid- (SAA-) free diet.” NCT00253773 ↗ “An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.” NCT00719472 ↗ “Patients are advised to take 1000 mg of acetaminophen every 6 hours and 600 mg of ibuprofen every 6 hours both scheduled and staggered 3 hours apart.” NCT07527039 ↗ “Antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) administered per product label prior to MK-6837.” NCT06460961 ↗ “An extended-release (ER) fixed-dose combination (FDC) of tramadol 37.5 mg/acetaminophen 325 mg was developed due to the demand for varying dosages.” PMID 35800670 ↗ Jun 2022 “Tylenol (compound oxycodone/acetaminophen) is a non-narcotic analgesic that combines a lower dose of oxycodone (5 mg) with acetaminophen (325 mg).” NCT07323914 ↗ “Paracetamol (APAP), also known as acetaminophen, is the most commonly used over-the-counter analgesic for the treatment of mild-to-moderate pain.” PMID 23972577 ↗ Aug 2013 “For the purposes of the current study we want to determine how much paracetamol (acetaminophen) can reduce the cytokines levels in these patients” NCT03221998 ↗ “Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs.” NCT00772967 ↗ “Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).” NCT03605914 ↗ “combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids” NCT04010266 ↗ “Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.” NCT00346151 ↗ “An antipyretic (e.g., oral acetaminophen \[15 mg/kg, 650 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab” NCT04743661 ↗ “Haemodynamic Effects of Paracetamol (Acetaminophen) as Extended Intravenous Infusion Versus Intravenous Bolus in Septic Shock Patients” NCT06076980 ↗ “Plasma glucose, insulin, and paracetamol (acetaminophen) concentrations (to assess gastric emptying) were measured pre- and postmeal.” PMID 21340616 ↗ Feb 2011 “in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours” NCT03193658 ↗ “Participants will take 5 mg/325 mg of oxycodone - acetaminophen every 6 hours as needed for pain, with a maximum of 4 doses per day.” NCT07154433 ↗ “COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)” NCT01451385 ↗ “1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days” NCT02929589 ↗ “fixed interval dosing of ibuprofen 600 mg along with acetaminophen 325 mg taken every 6 hours for the first 72 hours post-procedure” NCT07094542 ↗ “Our standard postoperative pain management plan consists of intercostal nerve block, patient-controlled analgesia and acetaminophen” NCT06861387 ↗ “* patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively” NCT01449708 ↗ “The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.” NCT04538573 ↗ “Oral acetaminophen (1 g) and diclofenac (50 mg) administered during the first 24 hours postpartum together every 8 houers” NCT07534969 ↗ “Group A, a combined and simultaneous therapy of 200 mg ibuprofen and 650 mg acetaminophen (3 pills total) taken orally” NCT04059172 ↗ “VYCAVERT (hydrocodone bitartrate and acetaminophen) compared to GENERIC H/A (hydrocodone bitartrate and acetaminophen)” NCT01759446 ↗ “one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery” NCT06174363 ↗ “Maxigesic® is a combination of acetaminophen and ibuprofen, and is a drug that rapidly relieves various types of pain.” NCT06015711 ↗ “If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.” NCT01374269 ↗ “Participants will receive the standard of care drug Norco (a medicine that combines hydrocodone and acetaminophen).” NCT07575230 ↗ “Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)” NCT04541147 ↗ “A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally” NCT03383133 ↗ “Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine.” NCT00940836 ↗ “Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics.” NCT06036784 ↗ “These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug.” NCT04562610 ↗ “oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)” NCT01011634 ↗ “hydrocodone bitartrate-acetaminophen (5 mg of hydrocodone bitartrate and 325 mg of acetaminophen every 6 hours)” PMID 37530822 ↗ Aug 2023 “After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered.” NCT03467750 ↗ “1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.” NCT02614118 ↗ “Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).” NCT04164823 ↗ “The analgesic and antipyretic paracetamol (acetaminophen) is generally considered safe in therapeutic doses.” PMID 41475826 ↗ Dec 2025 “Paracetamol (Acetaminophen) is mostly used for treating pain and fever, typically for mild to moderate pain.” NCT03060265 ↗ “Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules” NCT00921700 ↗ “butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg)” NCT00573170 ↗ “Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.” NCT00646906 ↗ “pain relievers such as acetaminophen and antidepressants such as Duloxetine (Cymbalta) and milnacipran” NCT07533487 ↗ “XARTEMIS XR [7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)] Extended-Release Tablets” NCT02508935 ↗ “Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit” NCT00652093 ↗ “Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain” NCT01402375 ↗ “Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.” NCT02269735 ↗ “Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen” NCT01971853 ↗ “The multimodal regimen comprised fixed-schedule doses of acetaminophen, meloxicam, and gabapentin.” PMID 31176028 ↗ Jun 2019 “Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.” PMID 36519620 ↗ Dec 2022 “perioperative IV (intravenous) administration of acetaminophen (commonly referred to as Tylenol)” NCT01823224 ↗ “Single 15 mL dose of oral solution of OC/APAP (total dose 15 mg oxycodone/975 mg acetaminophen)” NCT02966860 ↗ “Acetaminophen (325mg) + Hydrocodone (5mg) compared to Acetaminophen(325mg) + Ibuprofen (200mg)” NCT03584152 ↗ “with paracetamol (acetaminophen), morphine, buprenorphine transdermal patch, or pregabaline.” PMID 21765198 ↗ Jul 2011 “rescue analgesia with tramadol 37,5 mg + acetaminophen 325 mg oral fix combination (Patrol)” NCT02035904 ↗ “Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2)” NCT04254679 ↗ “Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)” NCT03951649 ↗ “ST will consist of 975mg of Acetaminophen PO and either 30mg of Ketorolac IM or 15 mg IV.” NCT04704297 ↗ “Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release” NCT04522206 ↗ “Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control” NCT03404518 ↗ “5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.” NCT00315445 ↗ “Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours” NCT04990804 ↗ “Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.” NCT01158326 ↗ “Acetaminophen (APAP) is commonly ingested in both accidental and suicidal overdose.” PMID 31768936 ↗ Nov 2019 “Consumption of 75 grams of glucose, diluted in water, added 1,5 g of acetaminophen.” NCT05310292 ↗ “Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment” NCT01958320 ↗ “Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet)” NCT03137017 ↗ “Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV” NCT03448068 ↗ “Oral treatment : 1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar” NCT00874172 ↗ “IV acetaminophen 15 mg/kg every 8 hours as a component of multimodal analgesia.” NCT05142176 ↗ “Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose” NCT00699114 ↗ “hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID)” NCT00385684 ↗ “acetaminophen (if necessary), elimination of irritating factors in the diet” NCT04537819 ↗ “it is preferable to use acetaminophen/paracetamol with fewer side effects.” NCT06256211 ↗ “The patients will receive intravenous analgesia with Acetaminophen (1g/6h)” NCT03775018 ↗ “acetaminophen (1000 mg orally) will be taken the morning of each infusion;” NCT03635957 ↗ “Acetaminophen PO dosed per body weight and discharged home with PO tabs” NCT06935331 ↗ “acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion” NCT04005755 ↗ “a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM” NCT03911336 ↗ “Patients shall receive 1,000 mg of acetaminophen orally every 6 hours” NCT01566838 ↗ “CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg” NCT02462850 ↗ “Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes” NCT04648540 ↗ “Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain” NCT00386243 ↗ “a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested” NCT01951716 ↗ “Both groups will also be given acetaminophen for the first 72 hours” NCT06973785 ↗ “Norco (acetaminophen/hydrocodone) 10/325 mg po q 6 hours PRN pain.” NCT02373254 ↗ “1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage” NCT04676802 ↗ “Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand” NCT01952314 ↗ “PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium” NCT04221165 ↗ “acetaminophen 1 gram by mouth (PO) every six hours up to 72 hours” NCT05393414 ↗ “The most commonly used analgesic is acetaminophen (paracetamol).” PMID 28754173 ↗ Jul 2017 “single preoperative dose of acetaminophen 1 g IV x1, gabapentin” NCT03330119 ↗ “Standard care with NSAIDs and acetaminophen for pain management” NCT06064058 ↗ “Paracetamol (Acetaminophen) 1 g orally twice daily for 14 days” NCT07349680 ↗ “* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg” NCT01734759 ↗ “fixed-dose ibuprofen 250 mg / acetaminophen 500 mg formulation” NCT02837952 ↗ “Tylenol - also known as acetaminophen 1000mg PO q8hr PRN pain” NCT06113211 ↗ “Adjunctive analgesics: acetaminophen, tramadol, or gabapentin” NCT01943435 ↗ “One gram of acetaminophen will be added to any NSAID intake.” NCT05761015 ↗ “Combination analgesic of hydrocodone 5mg/acetaminophen350 mg” NCT05283499 ↗ “Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.” NCT04941040 ↗ “medications like acetaminophen (0.5-1 g three times daily)” NCT06259474 ↗ “Hydrocodone 5 mg/Acetaminophen 325 mg/Promethazine 12.5 mg” NCT03657810 ↗ “20 tablets of Hydrocodone 5mg-Acetaminophen 325mg (Norco)” NCT03457116 ↗ “paracetamol (acetaminophen 15 mg/kg/dose every 6 hours)” NCT02401529 ↗ “Rectal acetaminophen at 15 mg/kg x 4/day for three days” NCT03604796 ↗ “one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet” NCT02312739 ↗ “PARACETAMOL (ACETAMINOPHEN) 500 mg PLUS CODEINE 30 mg” PMID 34922726 ↗ Jul 2021 “10 mg Hydrocodone (HC) / 325 mg acetaminophen (APAP)” NCT02197156 ↗ “telcagepant 280 mg + acetaminophen 1000 mg (N = 171)” PMID 21457238 ↗ Apr 2011 “oral gabapentin 600mg and oral acetaminophen 1,000mg” NCT03738904 ↗ “Acetaminophen 1g will be given prior to induction.” NCT03367988 ↗ “intravenous acetaminophen injection (paracetamol)” PMID 15791113 ↗ Apr 2005 “pre-operative dose of IV acetaminophen (ofirmev)” NCT02922985 ↗ “Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs” NCT04566250 ↗ “premedication with 500mg of acetaminophen orally” NCT06642025 ↗ “Paracetamol (acetaminophen) + Diclofenac Sodium” NCT06942702 ↗ “Oxycodone/acetaminophen 5 mg-325 mg oral tablet” NCT03173456 ↗ “Acetaminophen 15 mg/kg every 6 hours for 3 days” NCT02602054 ↗ “Hydrocodone Bitartrate/Acetaminophen (HB/APAP)” NCT03206749 ↗ “acetaminophen for central non-opioid analgesia” NCT07310524 ↗ “Hydrocodone bitartrate/acetaminophen (HB/APAP)” NCT05553366 ↗ “Acetaminophen IV 10-15 mg/kg 8hr postoperative” NCT05474040 ↗ “Hydrocodone bitartrate/acetaminophen (HB/APAP)” NCT06619847 ↗ “Hydrocodone bitartrate/acetaminophen (HB/APAP)” NCT05558410 ↗ “Oxycodone with Acetaminophen Extended Release” NCT02391844 ↗ “an antipyretic (ibuprofen or acetaminophen)” NCT03456817 ↗ “a 14-day supply of 1000mg acetaminophen BID” NCT07355166 ↗ “Acetaminophen: 2 pills two times per day.” NCT07447024 ↗ “celecoxib or acetaminophen, dose-adjusted” NCT07353372 ↗ “Hydrocodone Bitartrate and Acetaminophen” NCT07296770 ↗ “Acetaminophen 500Mg Tab x2 every 8 hours” NCT03640247 ↗ “IV acetaminophen 1g + IV ketorolac 30mg” NCT03534895 ↗ “Vicodin (acetaminophen and hydrocodone)” NCT04008043 ↗ “Hydrocodone 5mg + acetaminophen 325 mg” NCT01974609 ↗ “325 mg of paracetamol (acetaminophen)” NCT07204379 ↗ “Acetaminophen 650 to 1,000 mg orally” NCT05807048 ↗ “Naproxen + Oxycodone/ Acetaminophen” NCT01267825 ↗ “Acetaminophen 1000 mg by mouth once” NCT01211912 ↗ “Orally administered acetaminophen.” NCT03020875 ↗ “Paracetamol (Acetaminophen) Group” NCT05507554 ↗ “Drug: Paracetamol / Acetaminophen” NCT05405166 ↗ “Drug: Paracetamol (acetaminophen)” NCT07463482 ↗ “Acetaminophen label as high price” NCT01493908 ↗ “Acetaminophen 1000 mg po q6 hours” NCT04129086 ↗ “Hydrocodone/Acetaminophen group” NCT01859715 ↗ “intravenous (IV) acetaminophen” NCT02881996 ↗ “receive IV-acetaminophen (1 g)” NCT07211399 ↗ “Oxycodone/APAP(acetaminophen)” NCT02101476 ↗ “acetaminophen or paracetamol” NCT02845271 ↗ “Paracetamol / Acetaminophen” NCT07536425 ↗ “Paracetamol (acetaminophen)” NCT07022496 ↗ “Paracetamol (acetaminophen)” NCT07466108 ↗ “Paracetamol (acetaminophen)” NCT00508495 ↗ “Paracetamol (acetaminophen)” NCT00292214 ↗ “Paracetamol (acetaminophen)” NCT07711522 ↗ “Paracetamol (acetaminophen)” NCT07440069 ↗ “Paracetamol (Acetaminophen)” NCT06750627 ↗ “Paracetamol (acetaminophen)” NCT06861738 ↗ “Acetaminophen 500mg on need” NCT04591600 ↗ “Acetaminophen (Paracetamol)” NCT06420388 ↗ “Hydrocodone-acetaminophen” NCT02618395 ↗ “Acetaminophen 1g IV q6h” NCT04058444 ↗ “Acetaminophen 1000mg IV” NCT04197570 ↗ “acetaminophen 30mg,po.” NCT04237428 ↗ “Drug: Acetaminophen” NCT03391284 ↗ “Drug: Acetaminophen” NCT06187584 ↗ “oral acetaminophen” NCT06570577 ↗ “Acetaminophen IV” NCT03885596 ↗ |
| Known as | Abdine | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acamol | “Paracetamol (Acamol) 1,000 mg administered intravenously after induction of anesthesia, prior to oocyte retrieval.” NCT07536425 ↗ |
| Known as | ACE | “Acetaminophen (ACE) (1000 mg)” NCT02320708 ↗ |
| Known as | Acephen | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen (APAP) | “Acetaminophen (APAP)” NCT07101445 ↗ |
| Known as | acetaminophen / paracetamol | “acetaminophen / paracetamol” NCT03604796 ↗ |
| Known as | Acetaminophen component of allay | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of anexsia | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of anoquan | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of apadaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of bancap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of bancap hc | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of bucet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of butapap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of co-gesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of codrix | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of combogesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of combogesic iv | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of darvocet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of dhc plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of dolene ap-65 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of drixoral plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of duradyne dhc | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of esgic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of excedrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of femcet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of fioricet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of hy-phen | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of lorcet-hd | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of lortab | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of medigesic plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of norcet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of norco | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of oxycet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of percocet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of phrenilin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of roxicet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of roxilox | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of sedapap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of synalgos-dc-a | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of talacen | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of tencon | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of trezix | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of triad | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of triaprin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of tycolet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of tylox | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of ultracet | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of vicodin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of wygesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of xartemis | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen component of zydone | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Acetaminophen ER | “CONCLUSIONS: Acetaminophen ER 1300 mg, a nonprescription drug, given three times daily, can provide effective relief of signs and symptoms of osteoarthritis of the hip or knee...” PMID 25121804 ↗ Aug 2014 |
| Known as | acetaminophen extended release | “acetaminophen extended release caplets, 3900 mg/day (two 650 mg caplets taken three times a day, for four days)” NCT00240851 ↗ |
| Known as | Acetaminophen/Tylenol | “Acetaminophen: Tylenol” NCT00841841 ↗1“Acetaminophen/Tylenol” NCT02029235 ↗ |
| Known as | acetaminophene | “acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die” NCT01345162 ↗ |
| Known as | acetominophen | “Drug: acetominophen” NCT03391284 ↗ |
| Known as | acetyl-para-aminophenol | “Intravenous acetyl-para-aminophenol (APAP, also known as acetaminophen) is considered as the non-opioid analgesic of choice to treat postoperative mild and moderate pain” NCT01608308 ↗ |
| Known as | Acetylcystein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01771978 ↗ |
| Known as | ACP-iv | “the intravenous (iv) formulation (acetaminophen iv; ACP-iv) received US Food and Drug Administration (FDA) approval in November 2010” NCT02452320 ↗ |
| Known as | Alvedon | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Angiers | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | APAP | “Biphasic immediate-release (IR)/extended-release (ER) hydrocodone bitartrate (HB)/acetaminophen (APAP) 7.5/325-mg tablets are formulated with gastroretentive ER drug delivery...” PMID 26614499 ↗ Nov 201525“acetaminophen (APAP), N-acetylcysteine (NAC) and APAP in combination with NAC will inhibit lipid peroxidation in aneurysmal subarachnoid hemorrhage (aSAH), utilizing F2-IsoPs...” NCT00585559 ↗ “The objective of this study was to compare the analgesic efficacy of tramadol/acetaminophen (APAP) (total dose 75 mg/650 mg) and tramadol (total dose 100 mg) for the control of...” PMID 15157685 ↗ Jun 2004 “A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years” NCT07632274 ↗ “Intravenous acetyl-para-aminophenol (APAP, also known as acetaminophen) is considered as the non-opioid analgesic of choice to treat postoperative mild and moderate pain” NCT01608308 ↗ “The proposed model involves interaction of chemical exposure (2 doses of acetaminophen, APAP, 15 mg/kg) and 2 days of sulfur amino acid- (SAA-) free diet.” NCT00253773 ↗ “Paracetamol's (APAP) mechanism of action suggests the implication of supraspinal structures but no neuroimaging study has been performed in humans.” PMID 26229445 ↗ Jul 2015 “Paracetamol (APAP), also known as acetaminophen, is the most commonly used over-the-counter analgesic for the treatment of mild-to-moderate pain.” PMID 23972577 ↗ Aug 2013 “Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.” NCT00647517 ↗ “Acetaminophen (APAP) poisoning is the most frequent cause of acute hepatic failure in the United States.” NCT01246713 ↗ “XARTEMIS XR [7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)] Extended-Release Tablets” NCT02508935 ↗ “including lornoxicam, pregabalin, ibuprofen, gabapentin, and acetaminophen (APAP).” NCT07095816 ↗ “The effects of ASA are compared with those of acetaminophen (APAP) and placebo.” PMID 33191260 ↗ Nov 2020 “acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg)” NCT03383133 ↗ “10 mg Hydrocodone (HC) / 325 mg acetaminophen (APAP)” NCT02197156 ↗ “Hydrocodone Bitartrate/Acetaminophen (HB/APAP)” NCT03206749 ↗ “Acetaminophen (APAP)/Naproxen sodium (NPX)” NCT04447040 ↗ “Oxycodone/APAP(acetaminophen)” NCT02101476 ↗ “Drug: Acetaminophen/APAP” NCT01328808 ↗ “acetaminophen \[APAP\]” NCT00736957 ↗ “acetaminophen (APAP)” NCT00000731 ↗ “Acetaminophen (APAP)” NCT07013643 ↗ |
| Known as | APAP (acetaminophen) | “APAP (acetaminophen)” NCT01002573 ↗ |
| Known as | APAP: n-acetyl-p-aminophenol; acetaminophen; Tylenol | “APAP: n-acetyl-p-aminophenol; acetaminophen; Tylenol” NCT01137591 ↗ |
| Known as | Bernofarm | “Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.” NCT06604598 ↗ |
| Known as | Biocetamol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Calpol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Calpol six plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Calpol six plus fastmelts | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Child lemsip | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | codein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02252614 ↗ |
| Known as | Cupanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Dafalgan | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Disprol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Disprol infant | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Disprol jnr | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Disprol paed | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Doliprane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05681312 ↗ |
| Known as | Doliprane 500mg | “Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily” NCT01104337 ↗ |
| Known as | Efferalgan | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | ES-acetaminophen | “Two studies evaluated the analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets...” PMID 38124555 ↗ Jan 2024 |
| Known as | Extended-Release Hydrocodone/Acetaminophen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00404183 ↗ |
| Known as | FA-acetaminophen | “Two studies evaluated the analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets...” PMID 38124555 ↗ Jan 20241“This study was designed as the definitive trial evaluating the onset of pain relief of FA-acetaminophen versus these same OTC comparators.” PMID 38505928 ↗ Mar 2024 |
| Known as | Fennings | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Feverall() | “METHODS: Healthy male subjects (N = 6) were randomized to receive a single dose of IV (OFIRMEV(®) ; Cadence) 1,000 mg (15 minute infusion), PO (2 Tylenol(®) 500 mg caplets;...” PMID 22524979 ↗ Apr 2012 |
| Known as | Galpamol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | HB/APAP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07102459 ↗ |
| Known as | Hedex | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Infadrops | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Infant Calpol | “Children aged 1 month up to a weight of 25 kg and scheduled for elective surgery were randomly allocated to receive a prescribed 3.6 ml.kg-1 drink of water alone (water group)...” PMID 35166373 ↗ Feb 2022 |
| Known as | Infants' feverall | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Injectapap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | IV Acetaminophen (IV APAP) | “IV Acetaminophen (IV APAP)” NCT00598559 ↗1“IV Acetaminophen (IV APAP)” NCT00399568 ↗ |
| Known as | IV-A | “Intravenous Acetaminophen (IV-A)” NCT06994442 ↗ |
| Known as | Junior parapaed | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Mandanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medinol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medinol for children | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medinol over 6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medinol under 6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Medised plain | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Multimodal IV analgesia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07423650 ↗ |
| Known as | N-(4-hydroxyphenyl)acetamide | “Acetaminophen (N-(4-hydroxyphenyl)acetamide; paracetamol) is a mild analgesic whose main, but not sole, mechanism of action is thought to arise from inhibition of the...” NCT02452320 ↗ |
| Known as | N-ACC | “The aim of this study was to assess the effects of N-acetylcysteine (N-ACC) on contrast-induced nephropathy (CIN) defined by Cystatin C (Cys-C) serum levels and to evaluate the...” PMID 21710343 ↗ Jun 2011 |
| Known as | N-acetyl-p-aminophenol | “MNK-155, a biphasic (immediate-release/extended-release) hydrocodone bitartrate/N-acetyl-p-aminophenol (acetaminophen) (IR/ER HB/APAP) 7.5/325-mg fixed-dose combination analgesic agent” PMID 25913923 ↗ Apr 2015 |
| Known as | N-acetylcysteine | “The aim of this study was to assess the effects of N-acetylcysteine (N-ACC) on contrast-induced nephropathy (CIN) defined by Cystatin C (Cys-C) serum levels and to evaluate the...” PMID 21710343 ↗ Jun 2011 |
| Known as | N02B E01 Paracetamol (acetaminophen) | “N02B E01 Paracetamol (acetaminophen)” NCT00699114 ↗ |
| Known as | Neopap | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | NSC-109028 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | NSC-3991 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Ofiramev | “The study drug, Ofiramev® (acetaminophen) injection is a non-salicylate antipyretic and non-opioid analgesic agent.” NCT03051932 ↗ |
| Known as | Ofirmev | “These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug.” NCT04562610 ↗5“IV Paracetamol \[Ofirmev\] introduced every 6 hours after surgery” NCT06112548 ↗ “IV acetaminophen (Ofirmev™) as adjuvant analgesia” NCT01520298 ↗ “intravenous Acetaminophen (1000 mg Ofirmev)” NCT01773005 ↗ “Acetaminophen (Ofirmev)” NCT02369211 ↗ |
| Known as | OFIRMEV(TM) | “Product Information: OFIRMEV(TM) intravenous infusion, acetaminophen intravenous infusion.” NCT03020966 ↗ |
| Known as | P-hydroxy-acetanilid | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Paldesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol | “For PDA management, participants were randomly assigned to Group A, receiving oral paracetamol (Panadol, 15 mg/kg every 6 hours for 3 days), or Group B, receiving oral ibuprofen” NCT06601114 ↗3“Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches” NCT06095258 ↗ |
| Known as | Panadol actifast | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol actifast solb | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol advan | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol jnr | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panadol oa | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panaleve | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Panaleve 6 plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | PARA | “The reference product that the active treatments will be compared to is paracetamol (PARA) 500 mg.” NCT01938144 ↗ |
| Known as | Paracerol | “Paracetamol (Paracerol) 1 gram will be administered intravenously.” NCT03063658 ↗ |
| Known as | Paracerol (paracetamol) | “Paracerol (paracetamol)” NCT05125796 ↗ |
| Known as | paracetamol | “All patients will be submitted to the institution's standard management: multimodal analgesia with common analgesic (dipyrone 4 to 8 g / day or paracetamol 1500 to 2250 mg /...” NCT07666178 ↗564“The aim of the study was to compare the analgesic efficacy of intranasal tapentadol nasal spray 44.5mg and intravenous paracetamol 1gm during the postoperative period by Visual...” NCT05999890 ↗ “Thirty minutes before the end of surgery, nefopam 40 mg, paracetamol 1 g, and ketoprofen 100 mg will be administered intravenously, depending on the patient's comorbidities,...” NCT07207304 ↗ “A non-randomized, open-label study to investigate the effects of imatinib mesylate on the pharmacokinetics of acetaminophen/paracetamol in patients with newly diagnosed,...” NCT00428909 ↗ “patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy, Cascavel, PR, Brasil) and ketorolac tromethamine oral 10 mg (Toragesic® 10...” NCT03343392 ↗ “Eligible participants received a single dose of Co-Codamol capsules (2 x Paracetamol Ph Eur 500 mg, codeine phosphate hemihydrate Ph Eur 12.8 mg plus two placebo capsules) via...” NCT00281684 ↗ “An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating...” NCT05821517 ↗ “Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day,...” NCT06381063 ↗ “OBJECTIVE: To evaluate the effect of postoperative intravenous (IV) acetaminophen (paracetamol) vs placebo combined with IV propofol vs dexmedetomidine on postoperative...” PMID 30778597 ↗ Feb 2019 “Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg,...” NCT02246166 ↗ “FDC of codeine 30 mg/dipyrone 500 mg from Eurofarma Laboratórios SA (experimental drug) or the FDC of codeine 30 mg/paracetamol 500 mg (Tylex® - Janssen-Cilag Farmacêutica...” NCT04972292 ↗ “Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine...” NCT02922075 ↗ “The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30...” NCT02502877 ↗ “30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV...” NCT04248179 ↗ “Healthy women with ≤15 follicles identified by ultrasound undergoing oocyte retrieval under general anaesthesia (propofol) were randomised to receive IV paracetamol 1000 mg vs...” PMID 40451048 ↗ May 2025 “A fixed-dose combination of paracetamol, chlorphenamine and phenylephrine was safe and more effective than placebo in the symptomatic treatment of the common cold or flu-like...” PMID 24261438 ↗ Nov 2013 “Acetaminophen (paracetamol) has many pharmacological effects that might be beneficial in sepsis, including inhibition of cell-free hemoglobin-induced oxidation of lipids and...” PMID 38762798 ↗ Aug 2024 “Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine,...” NCT02463942 ↗ “Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine,...” NCT03956446 ↗ “Acetaminophen (N-(4-hydroxyphenyl)acetamide; paracetamol) is a mild analgesic whose main, but not sole, mechanism of action is thought to arise from inhibition of the...” NCT02452320 ↗ “Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low...” NCT03508167 ↗ “Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and...” NCT05673486 ↗ “Patients will receive conservative treatment Acetaminophen (paracetamol) 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.” NCT07095569 ↗ “Intravenous administration of paracetamol 1 g, morphine 0.1 mg/kg, dexamethasone 8 mg, and ketamine 0.5 mg/kg bolus followed by 0.3 mg/kg/h infusion for postoperative pain management.” NCT07455565 ↗ “Standard analgesia includes ketoprofen 100 mg twice daily and paracetamol 1000 mg every 8 hours for 24 hours after knee arthroplasty; morphine 10 mg IM as needed for rescue therapy.” NCT07059429 ↗ “will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia” NCT05874245 ↗ “Intravenous paracetamol 1 gr and a dose of 0,5 mg/kg-1 tramadol intravenously will be performed on all patients 30 min before the end of the surgery for postoperative analgesia.” NCT05621161 ↗ “Both groups will receive intravenous 400 mg ibuprofen and 100 mg tramadol 20 minutes before the end of the surgery, and routine 1000 mg paracetamol every 8 hours postoperatively” NCT07534488 ↗ “Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.” NCT06604598 ↗ “All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.” NCT02236260 ↗ “Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery.” PMID 15791113 ↗ Apr 2005 “BACKGROUND AND OBJECTIVE: Several features favor paracetamol (acetaminophen) administration by the intravenous rather than the oral route in the postoperative setting.” PMID 29214506 ↗ Mar 2018 “Evidence supports the use of anti-inflammatory drugs such as acetaminophen/paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) for mild cancer pain.” PMID 24799483 ↗ May 2014 “Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model.” PMID 27209292 ↗ Nov 2016 “The regimen includes Paracetamol (oral or intravenous) 1g/24 hour, Ibuprofen IV 1200 mg/24 hour, or Parecoxib 80 mg/24 hour IV, and Tramadol 100 mg IV.” NCT07139691 ↗ “Standard treatment for rotavirus which includes rehydration therapy and antipyretic therapy including sodium chloride fluid and paracetamol infusion” NCT07167797 ↗ “Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure.” NCT05904912 ↗ “The opioid-sparing group (100 participants randomized) received a prescription of naproxen, acetaminophen (paracetamol), and pantoprazole” PMID 36194219 ↗ Oct 2022 “A new formulation of paracetamol for intravenous administration has been manufactured in Greece by the industry Uni-Pharma (ΑPOTEL Μax®).” NCT02283203 ↗ “paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery” NCT05069311 ↗ “Systemic analgesia (SA) group continue to receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days.” NCT04482192 ↗ “Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion” NCT05298683 ↗ “Pharmacological treatment was administered by prescribing Miyorel, a combination of methocarbamol (380 mg) and paracetamol (300 mg).” NCT06583551 ↗ “paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).” NCT05222724 ↗ “Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen” PMID 15310785 ↗ Aug 2004 “Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.” NCT01421433 ↗ “Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration” NCT02613910 ↗ “using acetaminophen (Paracetamol and Maninitol Injection, Yichang Renfu Medicine Co., Ltd., China), 500 mg, intravenous bolus” NCT07235995 ↗ “Paracetamol, also called acetaminophen is an effective agent analgesic and antipyretic with weak anti-inflammatory activity.” NCT02582996 ↗ “Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)” NCT03762343 ↗ “Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required” NCT00547989 ↗ “A literature review of randomized clinical trials of intravenous acetaminophen (paracetamol) for acute postoperative pain.” PMID 21114616 ↗ Nov 2010 “Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.” NCT05507554 ↗ “modified "karolinska cocktail" (dextromethorphan, caffeine, losartan, omeprazole and paracetamol) before bariatric surgery” NCT01086722 ↗ “Analgesia Efficacy of Repeated Doses of Intravenous Acetaminophen (Paracetamol) in the Pediatric Spinal Fusion Population” NCT01394718 ↗ “Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients.” NCT01691690 ↗ “1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .” NCT06502067 ↗ “classic anesthetic strategy with postoperative analgesia associating Paracetamol and Morphine with standardized dose.” NCT07149077 ↗ “Combination of paracetamol and codeine in a fixed combination every 6 hours; maximum posology of codeine: 300mg/24h.” NCT03902340 ↗ “1g of IV paracetamol and 30 mg of IV Ketorolac will be given if intra-operative course suggest inadequate analgesia” NCT06202664 ↗ “All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.” NCT04314505 ↗ “Paracetamol (acetaminophen) was chosen, because it is rapidly and completely absorbed from all parts of the gut.” NCT01635608 ↗ “Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.” NCT06222333 ↗ “Arm 2- Patients will receive 15 mg/kg IV Paracetamol to a maximum of 1000 mg intravenously over 15 minutes.” NCT04123717 ↗ “The combination of ibuprofen and acetaminophen (paracetamol) may represent a viable nonopioid alternative.” PMID 29114833 ↗ Nov 2017 “Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)” NCT04255407 ↗ “routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)” NCT04546334 ↗ “Acetaminophen (Paracetamol) or Opioid Analgesia Added to Ibuprofen for Children's Musculoskeletal Injury” PMID 41505155 ↗ Mar 2026 “Acetaminophen (paracetamol) appears to be a promising alternative with possibly fewer adverse effects.” PMID 41697673 ↗ Apr 2026 “Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated” NCT04523831 ↗ “All patients had oral paracetamol 500mg, 4 times/day and diclofenac 75mg, 1 times/day after surgery.” NCT06630520 ↗ “Patients in this group will be treated with painkillers consisting of paracetamol and dexketoprofen.” NCT06222320 ↗ “Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.” NCT02269735 ↗ “patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid” NCT03060434 ↗ “1 symptomatic treatment (analgesic, antipyretic): a blister pack of 10 paracetamol 500 mg tablets” NCT05540470 ↗ “Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)” NCT05571046 ↗ “Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients” NCT03639389 ↗ “Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity.” NCT04745520 ↗ “If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV.” NCT02288923 ↗ “The capsules containing 400mg of paracetamol, 4 mg chlorpheniramine and 4mg phenylephrine.” NCT02735070 ↗ “All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.” NCT03167047 ↗ “premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo” NCT02604446 ↗ “2 tablets of "Acetaminophen (paracetamol)" 500Mg Tab administrated orally every 6 hours.” NCT03626753 ↗ “Postoperative Pain Difference for 'IV Paracetamol' and TAP Block' in Acute Cholecystitis” NCT04767542 ↗ “In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.” NCT04025606 ↗ “intravenous paracetamol( 1gram ) and pethidine IV (50 mg ) will be added when needed.” NCT03422354 ↗ “acetaminophen (paracetamol) will be administered orally to participants of both arms” NCT02180334 ↗ “paracetamol - 1-2 tablets (500-1000 mg) 2-3 times a day (if body temperature ≥38.0°)” NCT05783206 ↗ “oral combination of paracetamol (500mg) - ibuprofen (400mg) will be given to group A” NCT06146491 ↗ “Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.” NCT01158326 ↗ “A single fixed dose combination of ibuprofen 400 mg and paracetamol 500 mg 8 hourly” NCT03518463 ↗ “a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol” NCT00487110 ↗ “paracetamol 1g IV and ketorolac 30 mg IV in 100 mL normal saline intraoperatively” NCT07299630 ↗ “On days 37-40 the subject will be co-administered 1 gr paracetamol 4 times daily.” NCT02303106 ↗ “Postoperative analgesia includes paracetamol + ketorolac/parecoxib + metamizole,” NCT07337135 ↗ “Group P (group paracetamol, n = 30) was administered 1000 mg of IV paracetamol” PMID 30474791 ↗ Mar 2019 “Oral Paracetamol (500mg/6hr), IV Ketolac (15mg/6hr) and IV perfelgan (1gm/6hr)” NCT06958549 ↗ “Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day.” NCT04657952 ↗ “administering of IV paracetamol 1000 mg one hour prior to start of surgery” NCT04238377 ↗ “2 capsules of Ixprim® given orally (1000 mg Paracetamol + 75 mg Tramadol)” NCT01782846 ↗ “Patients receive 1000 mg of IV paracetamol every 6 hours postoperatively.” NCT07479069 ↗ “Acetaminophen (paracetamol) 20.0 mg/kg administrated by sublingual route” NCT02465255 ↗ “30 minutes after induction will be administered paracetamol 15 mg/kg iv.” NCT04294537 ↗ “Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D” NCT04935515 ↗ “suggest acetaminophen (paracetamol) as the oral analgesic to try first” NCT00110474 ↗ “a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM” NCT03911336 ↗ “Immediate postoperative analgesia at end of procedure: Paracetamol 1 g” NCT07414706 ↗ “one gram of paracetamol IV infusion at the beginning of the procedure” NCT06462573 ↗ “either dipyrone, acetaminophen (paracetamol) or valdecoxib/parecoxib” NCT00763997 ↗ “Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours.” NCT04172272 ↗ “1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)” NCT01408069 ↗ “TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).” NCT01764048 ↗ “Paracetamol (acetaminophen) efficacy and safety in the newborn.” PMID 22935063 ↗ Feb 2013 “paracetamol intravenous antipyretic (paracetamol 1gm/8 hours)” NCT05293132 ↗ “coanalgesics in the form of Paracetamol, Dexac, and Metamizol” NCT06390046 ↗ “Panadol-extra (565 mg: 500 mg paracetamol and 65 mg caffeine)” NCT03400111 ↗ “Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously” NCT04302129 ↗ “standard-of-care strategy using Paracetamol and Remifentanil” NCT05825560 ↗ “Postoperative: IV paracetamol 1 g every 6-8 hours scheduled;” NCT07658521 ↗ “Paracetamol as needed for the symptomatic treatment of fever” NCT04409483 ↗ “intravenous paracetamol (acetaminophen) 3 times daily” PMID 33345816 ↗ Apr 2019 “paracetamol 500\_1000 mg I.V every 6 hours for 5 days” NCT07032883 ↗ “Acetaminophen/Paracetamol (500 mg X 2 dosage units)” NCT00662818 ↗ “Paracetamol (07-day schedule - active comparator):” NCT04727424 ↗ “oral paracetamol was given as second line therapy” NCT03534869 ↗ “Acetaminophen (equivalent to paracetamol [para])” NCT07710729 ↗ “Paracetamol 1gram (2 tablets) / 8hr for 48 hours” NCT06446830 ↗ “Paracetamol 1g +/- Dexketoprofen trometamol 50mg” NCT04894864 ↗ “IV paracetamol 1 g/6 h + IV PCA morphine rescue” PMID 28192892 ↗ Feb 2017 “Morphine, Paracetamol, Dexketoprofen trometamol” NCT05172739 ↗ “Paracetamol 1000 mg every 8 hours will be given” NCT06750627 ↗ “1000mg intravenous injection of paracetamol” NCT06980727 ↗ “325 mg of paracetamol + 37.5 mg of tramadol” NCT06345716 ↗ “Acetaminophen (paracetamol) or equivalent” NCT04294459 ↗ “Tylex® (codeine 30 mg/paracetamol 500 mg)” NCT05081102 ↗ “paracetamol 500 mg as rescue medication” NCT07640126 ↗ “325 mg of paracetamol (acetaminophen)” NCT07204379 ↗ “1g of paracetamol as an I.V infusion” NCT04539249 ↗ “paracetamol (drug analgesic class1)” NCT04408560 ↗ “etoricoxib 120 mg, paracetamol 1 g” NCT00763685 ↗ “and paracetamol 1g every 8 hours.” NCT05702151 ↗ “1000 mg intravenous paracetamol” NCT01993589 ↗ “IV paracetamol 1g every 6 hours” NCT07268911 ↗ “Acetaminophen (Paracetamol)” NCT06420388 ↗ “acetaminophen (paracetamol)” NCT00137566 ↗ “Acetaminophen/Paracetamol” NCT04963296 ↗ “Acetaminophen/paracetamol” NCT05039619 ↗ “intravenous paracetamol” NCT02858622 ↗ “PO Paracetamol : 1 gram” NCT05136976 ↗ “paracetamol , Ketorolac” NCT03106818 ↗ “Paracetamol: 1g/8h IV” NCT07558226 ↗ “Paracetamol 1gx4” NCT07568938 ↗ “* Paracetamol” NCT07016451 ↗ “paracetamol” NCT04990388 ↗ |
| Known as | Paracetamol (Acetaminophen) | “Paracetamol (Acetaminophen)” NCT00921700 ↗1“paracetamol=acetaminophen” NCT01540838 ↗ |
| Known as | Paracetamol B. Braun | “Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi...” NCT07024199 ↗1“under the brand name Paracetamol® B. Braun, Germany” NCT03060265 ↗ |
| Known as | Paracetamol Kabi | “Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi...” NCT07024199 ↗ |
| Known as | Paracetamol UNIFLASH | “Comparison of the Analgesic Effect of a New Paracetamol Formulation (Paracetamol UNIFLASH) for Buccal Use and Two Different Doses of an Oral Paracetamol Form Controlled Versus...” NCT04640376 ↗ |
| Known as | Paracetamol-ratiopharm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04903509 ↗ |
| Known as | Paracetamol: Perfalgan | “Paracetamol: Perfalgan” NCT01069055 ↗ |
| Known as | Paracetamolum | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Paramin | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Parapaed jnr | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Parapaed six plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Paravict | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | parol | “1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients” NCT03768882 ↗3“1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 100 patients” NCT03918135 ↗ “1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)” NCT01993589 ↗ “Parol 500 mg Tablets (acetaminophen)” NCT03058224 ↗ |
| Known as | Perfalgan | “One hundred and thirty participants received either oral paracetamol and i.v. placebo (Group OP), or oral placebo and i.v. paracetamol (Perfalgan™) (Group IP).” PMID 23220855 ↗ Dec 2012 |
| Known as | Perfalgan infusion (paracetamol) | “Perfalgan infusion (paracetamol)” NCT03221998 ↗ |
| Known as | Placidex | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | PrACETAMINOPHEN INJECTION | “An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute...” NCT05557344 ↗ |
| Known as | Rimadol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Salzone | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tixymol | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tramil 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tylenol | “The ice packs, Tylenol, and Toradol regimen consists of around-the-clock ice packs, around-the-clock oral acetaminophen, around-the-clock intravenous ketorolac, and intravenous...” PMID 31201808 ↗ Jun 201940“Other pain medicines, like acetaminophen (also called Tylenol) and ketorolac (also called Toradol), are available but aren't commonly used because we don't know if they help.” NCT06994442 ↗ “The purpose of this study is to see whether giving acetaminophen (the medicine in Tylenol) for routine infant vaccinations is helpful in preventing fever or other symptoms.” NCT00325819 ↗ “Acetaminophen, often referred by the brand name, Tylenol, is also used to treat minor pains but is not commonly recognized to cause damage to the stomach lining.” NCT00594867 ↗ “The addition of acetaminophen (Tylenol) to opioids in a small study in cancer patients demonstrated better pain control without an increase in side effects.” NCT00152854 ↗ “The purpose of this study is to see if acetaminophen (Tylenol) is as effective as indomethacin in closing patent ductus arteriosus in premature infants.” NCT03537144 ↗ “Paracetamol 750 mg (Tylenol© - Johnson \& Johnson), 01 tablet every 6 hours, by oral administration, for control of postoperative pain” NCT02238288 ↗ “Paracetamol suppository 350 mg (Tylenol CILAG SA, Schaffhouse, Switzerland) will be administered for children with pain scores <4.” NCT02355678 ↗ “Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given.” NCT00267293 ↗ “Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery” NCT04766996 ↗ “3. Tylenol 1000 mg three times per day from postoperative day 1 to postoperative day 14.” NCT06561035 ↗ “Acetaminophen (Tylenol) is a commonly used medication after surgery to control pain.” NCT06923540 ↗ “This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral.” NCT05144828 ↗ “with Tylenol 8 hour extended release gel tabs (containing acetaminophen 650 mg)” NCT01523080 ↗ “medications such as Gabapentin, Tylenol, Meloxicam, Bupivacaine, or Ketorolac.” NCT04176783 ↗ “intravenous acetaminophen (Tylenol) for post operative pain control” NCT03261310 ↗ “A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)” NCT05428293 ↗ “Tylenol - also known as acetaminophen 1000mg PO q8hr PRN pain” NCT06113211 ↗ “This medication is more commonly known as Tylenol.” NCT04662567 ↗ “* Tylenol: 1000mg po q 8hr (scheduled)” NCT02219581 ↗ “acetaminophen (also known as Tylenol)” NCT04905563 ↗ “use of IV tylenol for pain” NCT04093219 ↗ “acetaminophen / Tylenol” NCT02209181 ↗ “Tylenol® 975mg per os” NCT01511627 ↗ “* Tylenol 1000mg q8h” NCT05231460 ↗ “Tylenol/Motrin” NCT03528343 ↗ |
| Known as | Tylenol (Acetaminophen) | “Tylenol (Acetaminophen)” NCT04423107 ↗ |
| Known as | Tylenol (caplet) | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tylenol (geltab) | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | Tylenol Arthritis Pain | “Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)” NCT01079078 ↗1“Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)” NCT01073709 ↗ |
| Known as | Tylenol caplets | “Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)” NCT05428306 ↗ |
| Known as | Tylenol extra strength | “Acetaminophen (Tylenol extra strength)” NCT01420094 ↗ |
| Known as | TYLENOLÒ arthritis pain | “TYLENOLÒ arthritis pain caplets 650 mg (containing acetaminophen 650 mg)” NCT01079078 ↗ |
| Known as | Uniflash | “paracetamol Uniflash (125 mg/ 1.25 mL)” NCT05406752 ↗ |
| Known as | Vermidon | ChEMBL registry synonym — accepted as the source's own label CHEMBL112 ↗ |
| Known as | ΑPOTEL max | “Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes.” NCT02283203 ↗ |
| Known as | ΑPOTEL Μax | “A new formulation of paracetamol for intravenous administration has been manufactured in Greece by the industry Uni-Pharma (ΑPOTEL Μax®).” NCT02283203 ↗ |
| Action | Activate | “Vanilloid receptor opener” CHEMBL112 ↗ |
| Action | Inhibit | “acetaminophen (APAP) is a potent inhibitor of hemoprotein-catalyzed lipid peroxidation” NCT00585559 ↗1“Anandamide amidohydrolase inhibitor” CHEMBL112 ↗ |
| Modality | Small molecule | “Acetaminophen is a synthetic nonopioid p-aminophenol derivative” NCT03295214 ↗ |
| Route | Oral | “APAP orally every 8 hours” NCT00000731 ↗ |
| Target | FAAH | “Anandamide amidohydrolase inhibitor” CHEMBL112 ↗ |
| Target | TRPV1 | “Vanilloid receptor opener” CHEMBL112 ↗ |